文献速递神经肿瘤

丘脑胶质瘤的临床与分子特征:26例回顾性报告

Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases.
PubMed 文献 · World Neurosurg · 2019-03-16

该研究回顾性分析2011年1月至2015年8月在上海华山医院接受手术的26例中国丘脑胶质瘤患者的临床与分子特征及预后影响因素。H3K27M突变见于12例,突变组MGMT启动子甲基化频率低于野生型组(P=0.015;χ1检验)。多因素分析显示H3K27M突变是总生存的独立不良预后因素,MGMT启动子未甲基化和TP53突变是无进展生存的独立不良预后因素。

要点

  • 丘脑胶质瘤最常见首发症状为头痛(38.46%;10/26)和运动障碍(30.77%;8/26)。
  • H3K27M突变组MGMT启动子甲基化频率低于野生型组(P=0.015;χ1检验)。
  • H3K27M突变是总生存的独立不良预后因素;MGMT启动子未甲基化和TP53突变是无进展生存的独立不良预后因素。

核心结论

  • H3K27M突变组MGMT启动子甲基化频率低于野生型组(P=0.015;χ1检验),验证其作为H3K27M突变胶质瘤标志。
  • H3K27M突变是总生存的独立不良预后因素。
  • MGMT启动子未甲基化和TP53突变是进展无生存的独立不良预后因素。

研究设计与样本

  • 回顾性分析2011年1月至2015年8月在上海华山医院接受手术的26例丘脑胶质瘤患者的临床与分子资料。

主要发现

  • 患者平均年龄38.88岁,性别差异无统计学意义。
  • 最常见首发症状为头痛(38.46%;10/26)和运动障碍(30.77%;8/26)。
  • H3K27M突变见于12例患者,突变组MGMT启动子甲基化频率低于野生型组(P=0.015;χ1检验)。
  • 多因素分析显示H3K27M突变是总生存的独立不良预后因素。
  • MGMT启动子未甲基化和TP53突变被确定为无进展生存的不良预后因素。

临床怎么用

  • 在丘脑胶质瘤中可检测H3K27M突变状态,其与MGMT启动子甲基化缺失相关且与总生存不良相关。
  • 可评估MGMT启动子甲基化和TP53突变状态,其与无进展生存不良相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thalamic glioma is a type of midline glioma with poor outcomes. In the present study, we investigated the clinical and molecular features of thalamic gliomas in Chinese patients. METHODS: The data from 26 patients with thalamic glioma who had undergone surgery at Shanghai Huashan Hospital from January 2011 to August 2015 were retrospectively analyzed. Various clinical and molecular factors were evaluated to explore their effects on prognosis. H3K27M mutation status and its association with relevant molecular factors were also investigated. RESULTS: The mean age of the patients was 38.88 years, and no significant difference was found in sex. The most common initial symptoms were headaches (38.46%; 10 of 26) and motor deficits (30.77%; 8 of 26). The H3K27M mutation was identified in 12 patients, and mutant thalamic glioma showed less frequent O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation compared with the wild-type group (P = 0.015; χ1 test). Multivariate analysis showed that the H3K27M mutation was an independent unfavorable prognostic factor for overall survival. MGMT promoter unmethylation and the TP53 mutation were identified as negative prognostic factors for progression-free survival. CONCLUSIONS: Our results revealed the clinical and molecular characteristics of thalamic glioma in China. Our data have shown the absence of MGMT promoter methylation in H3K27M mutant thalamic glioma, validating it as a hallmark of H3K27M mutant gliomas. In addition, H3K27M mutation was identified as the sole unfavorable prognostic factor on overall survival. MGMT promoter unmethylation and TP53 mutation were identified as independent prognostic factors for progression-free survival.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu Y, Zhang Y, Hua W, et al. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases. World Neurosurg. 2019. PMID: 30885860. doi:10.1016/j.wneu.2019.03.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。